Please wait while we open this resource.
K
Clinical reviews
Combination of GM CSF and carbapenem is superior to carbapenem monotherapy in difficult- to- treat spontaneous bacterial peritonitis: A randomized controlled trial
Institute of Liver and Biliary Sciences, New Delhi, India
PDF20239 pages587 KB
The research presents a randomized controlled trial involving 131 patients with difficult-to-treat spontaneous bacterial peritonitis (SBP). The trial compares the treatment outcomes of patients receiving meropenem alone versus those receiving meropenem in combination with GM-CSF. Results indicate that the combination therapy significantly improves early response and resolution rates of SBP, as well as reduces the incidence of complications such as acute kidney injury and infections.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
Hepatitis E Virus, Second Edition (Springer, 2023)
Same clinical topic · Hepatology
AUTOIMMUNE HEPATITIS
Same clinical topic · Hepatology
MOLECULAR MECHANISMS AND PATHOGENESIS OF MASH
Same clinical topic · Hepatology
CIRRHOSIS, PORTAL HYPERTENSION AND HEPATOCELLULAR CARCINOMA: A STAGE-BASED APPROACH
Same clinical topic · Hepatology
NEW APPROACHES TO CHRONIC HEPATITIS B
Same clinical topic · Hepatology
CURRENT THERAPEUTIC LANDSCAPE AND FUTURE TREATMENT PERSPECTIVES OF MASH
Same clinical topic · Hepatology
RANDOMIZED, CONTROLLED CLINICAL TRIAL OF THE DIALIVE LIVER DIALYSIS DEVICE VERSUS STANDARD OF CARE IN PATIENTS WITH ACUTE ON-CHRONIC LIVER FAILURE
Same clinical topic · Hepatology
Intravenous albumin after outpatient paracentesis reduces the risk of AKI hospitalization: A national cohort study
Same clinical topic · Hepatology
LIVER TRANSPLANTATION FOR PATIENTS WITH SEVERE ACUTE ON CHRONIC LIVER FAILURE: IT IS TIME TO CHANGE PARADIGMS
Same clinical topic · Hepatology